考察健康试验参与者在空腹条件下，单次口服3片由湖南华纳大药厂股份有限公司提供的贝前列素钠缓释片（受试制剂，规格：60μg）或单次口服3片由Toray Industries, Inc.持证的贝前列素钠缓释片（参比制剂，商品名：Careload®LA，规格：60μg）的药动学特征，初步评估两制剂的生物等效性。

开始日期2026-04-06

申办/合作机构

湖南华纳大药厂股份有限公司

CTR20255059

/ CompletedN/A

贝前列素钠片空腹及餐后人体生物等效性研究

以山东新时代药业有限公司生产的贝前列素钠片（规格：20μg）为受试制剂，Toray Industries, Inc.持证的的贝前列素钠片（商品名：Dorner®/德纳®，规格：20μg）为参比制剂，考察两制剂在空腹及餐后状态下单次给药吸收速度和程度的差异，评价两制剂是否具有生物等效性。

开始日期2026-01-14

申办/合作机构

山东新时代药业有限公司

ChiCTR2500109121

/ Suspended临床4期IIT

Study on the effectiveness and safety of Beiprostate Sodium in the treatment of acute cerebral infarction

开始日期2025-09-19

申办/合作机构

重庆医科大学附属第一医院

100 项与贝前列素钠相关的临床结果

登录后查看更多信息

100 项与贝前列素钠相关的转化医学

登录后查看更多信息

100 项与贝前列素钠相关的专利（医药）

登录后查看更多信息

900

项与贝前列素钠相关的文献（医药）

2026-04-01·Lancet Regional Health-Europe

Multimorbidity phenotypes and associated characteristics in severe asthma: an observational study of European severe asthma registries

Article

作者: Damadoglu, Ebru ; Heffler, Enrico ; Grle, Sanja Popović ; Kuna, Piotr ; Brinke, Anneke Ten ; Adcock, Ian ; Paróczai, Dóra ; Schleich, Florence ; Horvath, Ildiko ; Goksel, Ozlem ; Roberts, Graham ; Dahlen, Barbro ; Mihaltan, Florin ; Singh, Mehar ; Bansal, Aruna T ; Haitchi, Hans Michael ; Rizzi, Angela ; Kroica, Iveta ; Kopač, Peter ; Siddiqui, Salman ; Pereira, Ana M ; Dimic-Janjic, Sanja ; Hromis, Sanja ; Bonini, Matteo ; Lúðvíksdóttir, Dóra ; Maria Luigia Costanzo, Giulia Anna ; Canonica, Giorgio Walter ; Bieksiene, Kristina ; Štajduhar, Anamarija ; Zappa, Martina ; Csoma, Zsuzsanna ; Djukanovic, Ratko ; Gemicioglu, Bilun ; Milenkovic, Branislava ; Varkonyi-Sepp, Judit ; Caminati, Marco ; Rink, Saša ; Yasinska, Valentyna ; Principe, Stefania ; Kurukulaaratchy, Ramesh J ; Brussino, Luisa ; Freeman, Anna ; Matisa, Dace ; Hou, Ruihua ; Frankemölle, Betty ; Škrgat, Sabina ; Heaney, Liam ; Bossios, Apostolos ; Hodge, Hilary ; Bourdin, Arnaud ; Hyland, Michael ; Sont, Jacob K ; Loureiro, Cláudia Chaves ; Egesten, Arne ; Ainsworth, Ben ; Kalinauskaite-Zukauske, Virginija ; Brusselle, Guy ; Chaudhuri, Rekha ; Porsbjerg, Celeste ; Spanevello, Antonio

Background:

The phenotypic nature of multimorbidity in severe asthma is poorly understood. Our aims in this study were to define multimorbidity phenotypes and their characteristics in severe asthma across Europe by identifying and characterising co-aggregation of comorbidities.

Methods:

Cross-sectional patient data were analysed from the pan-European Severe Heterogenous Asthma Research Collaboration: Patient Centred (SHARP) Central database of national severe asthma registries. Patients were grouped by four European regions (North, South, East, and West). Hierarchical clustering of comorbidities was applied to characterise the correlation structure of the ten commonest comorbidities within these geographical regions. Subsequent multimorbidity phenotypes (MMP) and their clinical features were then defined.

Findings:

Data were available for 2690 severe asthma patients and 23 comorbidities from 11 countries. Three comorbidity clusters were consistently seen across the four European regions: 1) osteoporosis plus steroid-induced weight gain, 2) eczema plus rhinitis, and 3) chronic sinusitis plus nasal polyps. Four further comorbidities (obesity, bronchiectasis, gastro-oesophageal reflux disease, psychological factors) showed variable clustering. Multimorbidity was ubiquitous. Patients were assigned multimorbidity phenotypes (MMP) according to comorbidity cluster alignment. MMP sn (sinonasal-associated) and MMP u (no specific cluster alignment) were commonest. MMP ster (steroid-associated multimorbidity) had highest maintenance oral steroid (m-OCS) use, and Body Mass Index, plus worst lung function, asthma control, and asthma exacerbation frequency. MMP max (maximal multimorbidity) showed high prevalence of variably assigned comorbidities, higher m-OCS and biologic treatment needs.

Interpretation:

Multimorbidity is common in severe asthma and can be classified into replicable novel phenotypes with characteristic clinical traits and outcomes. Recognising these phenotypes can guide better care of the 'whole patient' with severe asthma. Future clinical guidance should promote such understanding in order to support delivery of more effective personalised asthma care.

Funding:

European Respiratory Society, pharmaceutical industry partners (Sanofi, TEVA, Novartis, GlaxoSmithKline, Chiesi).

2026-03-01·JPRAS open

Delayed-onset functional ischemia 16 years after digital replantation: A Raynaud’s-like vasospasm case report

Article

作者: Ren, Yixin ; Liang, Zhen ; Wu, Ziyu ; Song, Baoqiang

Reports of long-term complications following finger replantation are scarce. Vascular crises occurring more than a decade after surgery are particularly rare. We present the case of a 27-year-old male who developed with acute cyanosis and reduced skin temperature of the left index finger, occurring 16 years after digital replantation. The patient had undergone replantation of the left index and middle fingers in childhood. He reported chronic smoking and frequent cold-water exposure prior to symptom onset. Imaging demonstrated narrowing of the proper palmar digital artery of the index finger, with diminished distal perfusion and no evidence of mechanical obstruction. Ambulatory blood pressure monitoring revealed uncontrolled hypertension (141/101 mmHg). Based on his risk factors and imaging findings, a diagnosis of vasospastic ischemia, consistent with a Raynaud's-like phenomenon likely triggered by tobacco use and cold exposure, was made. The patient responded well to infrared thermotherapy and vasoactive agents (nifedipine, bisoprolol, and beraprost sodium), with complete resolution of symptoms. This case highlights that replanted digits, due to incomplete reconstruction of the microvascular network, may remain vulnerable to vasospastic insults even many years later. It underscores the importance of lifelong risk mitigation, particularly the avoidance of reversible triggers such as smoking and cold exposure.

2026-02-06·ORGANIC LETTERS

Seeking Equality from an Asymmetric System: The Convergent Total Synthesis of Prostacyclin Drug (±)-Beraprost Sodium

Article

作者: Pan, Jingfan ; Zhang, Xiangyu ; Wang, Tianyu ; Zhu, Xinyu ; Jiang, Sheng ; Wang, Ting ; Chen, Taobin ; Qi, Zhihao

(±)-Beraprost sodium is an oral prostacyclin drug used to treat pulmonary arterial hypertension (PAH). It exists as a mixture of two C-4 diastereomers in a ratio of approximately 1:1, which presents significant challenges for process development. Herein, we report a novel and convergent total synthesis of (±)-beraprost sodium that enables precise control over the C-4 stereochemistry. This synthesis features key transformations including the Mitsunobu reaction, ring-closing metathesis, intramolecular Heck reaction, and cross-electrophile coupling, providing an efficient route to the target compound. Furthermore, systematic investigation into Horner-Wadsworth-Emmons olefination and ketone reduction has yielded a robust method for achieving the desired 1:1 diastereomeric ratio at C-4 from the asymmetric skeleton.

355

项与贝前列素钠相关的新闻（医药）

2026-07-10

·药通社

刚刚，中国创新药，印度药企拿下首仿！

刚刚，NMPA发布批准件，贝达药业中国第一个自主创新的小分子靶向抗癌新药埃克替尼，被印度瑞迪仿制成功了。贝达药业的埃克替尼声名显赫，是我国自主研发的一款一代EGFR-TKI，2011年5月，埃克替尼片剂首次在国内获批上市，商品名为凯美纳。当时国内的创新药环境与今日可谓天壤之别，作为具有自主知识产权的靶向抗癌药物，埃克替尼吸引了无上的关注目光。该药物可用于二线治疗局部晚期或转移性非小细胞肺癌（NSCLC）、一线治疗EGFR突变型局部晚期或转移性NSCLC和术后辅助治疗EGFR突变型II-IIIA期NSCLC。凭借先发及稀缺优势，凯美纳的商业化非常成功，据贝达药业的财报计算，埃克替尼已为贝达带来累计超百亿元的营收贡献。不过EGFR-TKI目前已更新至第三代，第三代阿美替尼，伏美替尼现如今已成临床常用，埃克替尼压力很大。在此情形下，2022年8月，贝达的凯美纳被列为参比制剂，但由于EGFR-TKI更新迭代太快，所以大家并没有什么仿制意愿，自始至终仅有这一家印度企业提交了仿制申请。埃克替尼的化合物专利已于2023年到期。不过，受晶型等多项相关专利权保护，其保护期可延长至2029-2034年。近些年，围绕贝达的争议一直不断，埃克替尼越辉煌，就越有人担忧贝达对其单一品种的严重依赖，事实上，埃克替尼曾一度占据贝达超9成营收。压力之下，贝达这些年也一直在致力于寻找开发新的大单品，2020年贝达第二款新药恩沙替尼成功获批上市，而这距离埃克替尼上市已经过去了9年。截至目前，贝达共有6款新药上市——分别为凯美纳（埃克替尼）、贝美纳（恩沙替尼）、贝安汀(贝伐珠单抗注射液）、赛美纳(贝福替尼）、伏美纳(伏罗尼布片)、康美纳（酒石酸泰瑞西利胶囊）。虽然新药上市节奏并不快，但商业化表现很不赖。今年一季度的贝达给出了一份很漂亮的答卷，2026年一季度公司实现收入10.4亿元，同比增长13.33%，扣非净利润达到2.07亿元，同比增长26.02%。而其中埃克替尼收入仅占据28%（2023年埃克替尼仍占贝达药业总收入近60%）。从目前情况下，埃克替尼已经不是贝达现在唯一可以倚仗的产品，贝达另一重磅单品恩沙替尼保持高速增长，2023-2025年分别实现6.31亿元、8-9亿元、10亿元；同时三代EGFR-TKI贝福替尼也在高速增长。看向另一边，首仿企业印度瑞迪，没想到埃克替尼这个中国代表性创新药品种，首仿竟然是印度企业。瑞迪博士我们也很熟悉了，应该是目前在中国扎根最稳的印度药企，这家企业是印度最早国际化的仿制药巨头之一，很早就进入中国布局。不过虽然进入中国早，但印度药企贸然想在一个新国家开拓出新市场，难度极高。因此会发现瑞迪这几年一直在非常努力参加中国的集采，最早在4+7扩围阶段就中标了奥氮平片，且价格相当可以，当时高于齐鲁一倍多。靠着这个品种，瑞迪在国内成功站稳了脚跟。几年下来，奥氮平片累计为其带来了超50亿累计销售额。在此之后，尝到了甜头的瑞迪也是一直在积极参与国采，就在去年的11批中，更是一举斩获四个品种：尼麦角林片、氟伏沙明片、贝前列素钠片、罗沙司他胶囊。深度分析文章：印度仿制药，攻进来了！其中最核心的产品就是尼麦角林片。在这个品种上，昆山龙灯瑞迪非常强势，不仅是当前国内市场份额最大的企业，同时也是此次集采收获报量最多的企业，达到首年需求量50%。这个成绩相当出色了，瑞迪的尼麦角林非原研，一个印度仿制药，能在首次引入报量机制的11批国采拿下超半数报量，足见其根基之深。印度企业，攻进来了！ ps：现如今仿制药立项越来越难，能做的品种几乎见底，参比目录数量也是一批比一批少，在这种情况下，选择部分优质国内新药进行仿制不失为一种可能性。附：列入参比目录的39个国产创新药 ↓⭐关注药通社，洞见行业趋势↓

2026-07-09

·allsci.com

Teva signs global licensing deal for Polpharma’s ocrelizumab biosimilar

Teva Pharmaceutical Industries (NYSE and TASE: TEVA) has entered a global licensing agreement with Switzerland-based Polpharma Biologics International AG, securing exclusive rights to commercialize Polpharma’s proposed biosimilar to ocrelizumab (Ocrevus; Roche/Genentech) across the US, EU, Brazil, Canada, Australia, New Zealand, Israel, and Turkey. The deal covers both the intravenous and subcutaneous formulations of the candidate, internally designated PB018. Polpharma retains full responsibility for development and manufacturing; Teva will handle regulatory submissions and commercialization in the licensed markets. Financial terms were not disclosed. Why it matters Ocrelizumab generated approximately USD 7.9 billion in annual global sales for Roche in 2025, making it one of the largest remaining biosimilar opportunities not yet secured by a major commercial partner across Western markets. The deal’s dual-formulation scope is structurally notable: Roche’s subcutaneous version, Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq), received US FDA approval in September 2024 and is actively shifting prescriber preference away from the four-hour IV infusion. By securing rights to both formulations upfront, Teva avoids being stranded on a legacy IV product in a market migrating toward subcutaneous administration by the time PB018 could launch. Deal context This agreement represents the most commercially significant entry in Teva’s biosimilar in-licensing program, which has followed a consistent capital-light template: the developer retains manufacturing and clinical risk, while Teva contributes regulatory infrastructure and commercial reach. The same structure governed Teva’s January 2025 agreement with Samsung Bioepis for an eculizumab biosimilar (US-only scope) and its April 2024 and October 2024 agreements with mAbxience for oncology biosimilars — the latter involving USD 15 million in combined upfront and milestone payments, providing a rough benchmark for Teva’s biosimilar deal economics. For Polpharma, the Teva agreement functions as the anchor transaction in a deliberate geographic carve-out strategy for PB018. The MENA region was licensed to MS Pharma in September 2025, and Latin America excluding Brazil was licensed to Tuteur in May 2026. Polpharma has previously demonstrated the commercial viability of this model: its natalizumab biosimilar Tyruko launched in the US in November 2025 under a Sandoz commercialization partnership, establishing precedent for licensing MS biosimilars while retaining manufacturing. Industry and transaction context The ocrelizumab biosimilar field is crowded and competitive. Samsung Bioepis added ocrelizumab to its pipeline in January 2026; Amgen completed a Phase III trial in early 2025; Celltrion is in active Phase III development. Teva’s deal does not guarantee first-mover advantage — the commercial outcome will depend heavily on PB018’s clinical development timeline relative to primary patent expiries (US: approximately October 2028; EU: March 2028) and on Teva’s ability to secure formulary positioning in a multi-biosimilar market. The geographic breadth of the Teva deal is unusual for a single-asset biosimilar commercialization agreement. Most structurally comparable transactions — including Polpharma’s own vedolizumab deal with Fresenius Kabi, announced in August 2025, which excluded MENA — are regionally scoped. Covering US, EU, and multiple additional markets in a single agreement suggests Teva commanded a premium for its global commercial infrastructure, or that Polpharma prioritized execution certainty over maximizing per-region economics. The reference product’s scale — and the compressed timeline to the patent window — likely made both considerations relevant. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Copyright © 2026. AllSci Corp. All rights reserved.

引进/卖出临床3期上市批准

2026-07-08

·Innodrugs

Teva旗下IL-15 抗体准备推进至白癜风 2b 期临床开发阶段

以色列特拉维夫，2026年7月7日——Teva Pharmaceutical Industries Ltd.（纽交所、特拉维夫证券交易所股票代码：TEVA）今日公布研发规划，计划于2026年第四季度将自研在研抗白介素15单克隆抗体TEV-’408推进至白癜风2b期临床试验。该决策基于一项正在开展、针对活动性或稳定型非节段型白癜风（NSV）成人患者的开放标签1b期研究取得积极临床数据。 1b期开放标签研究核心数据这项仍在进行的开放标签1b期研究结果显示，活动性及稳定型NSV患者皮肤色素沉着均出现改善，TEV-’408整体耐受性良好，截至目前未观察到明显安全风险信号。入组基线数据显示，66%受试者白癜风皮损面积占体表面积10%以上，这类患者现有治疗选择十分有限。第24周可评估受试者数据如下： - 近75%患者面部白癜风皮损得到改善，其中半数患者评价改善程度为“明显改善”或“极大改善”； - 42%患者达到F-VASI50，21%患者达到F-VASI75； - 55%患者全身白癜风皮损出现改善； - 7%患者达到T-VASI50。 Teva总裁兼首席执行官Richard Francis表示：“TEV-’408是公司自主研发创新管线的典型代表，也是我们免疫学科研管线重点推进项目。该药物具备扎实的生物学机制，针对临床未被满足的重大治疗需求，充分体现公司‘增长转型’战略落地成效，也彰显我们持续为患者打造差异化创新疗法的决心。” 白癜风是慢性自身免疫性疾病，会造成皮肤色素脱失，严重影响患者生活质量、自我认知与日常社交。尽管近年相关治疗有所进展，但临床可选方案仍十分有限，尤其皮损范围较大、需要全身系统治疗，或是追求更好病情控制效果的患者，治疗缺口显著。 Teva全球研发执行副总裁、首席医学官Eric Hughes医学博士、哲学博士表示：“白癜风带来的影响远不止皮肤外观，它会改变患者自我认知、日常社交状态与自信心。本次积极临床数据进一步印证IL-15通路的治疗价值，也体现Teva深厚的科研实力。我们十分看好这款管线药物的潜力，有望为白癜风患者带来全新有效的治疗方案。” TEV-’408 1b期试验设计本次开放标签1b期研究入组成人活动性/稳定型NSV患者，入组标准为F-VASI＞0.5或T-VASI＞5。给药方案为第0天、第12周各进行一次皮下注射。主要疗效终点为第24周白癜风面积严重程度指数（VASI），患者随访持续至第80周。关于TEV-’408 TEV-’408由Teva自主研发，是一款在研全人源单克隆抗体，作用靶点为免疫通路关键细胞因子白介素15（IL-15）。体外实验证实该分子靶点亲和力高、药效强，且半衰期长，拟定便捷的每12周一次皮下注射给药方案。除白癜风适应症临床开发外，TEV-’408用于乳糜泻的2a期临床研究正在推进，该适应症已于2025年5月获美国FDA快速通道资格认定。 TEV-’408通过阻断IL-15活性，实现两种治疗作用：一是减少免疫介导的黑素细胞（色素生成细胞）损伤，改善白癜风特征性皮肤白斑；二是抑制IL-15介导的肠道炎症与黏膜损伤，用于乳糜泻治疗。此前公司已公布与Royalty Pharma达成合作，对方最高提供5亿美元战略研发资金，加速TEV-’408全管线临床开发，包含本次计划开展的白癜风2b期研究。关于白癜风白癜风是慢性自身免疫性皮肤病，核心特征为色素生成细胞（黑素细胞）受损缺失，全身各处均可出现白斑。该病可累及各年龄段、各类肤色及种族人群，全球患病率约0.5%–2%，仍有大量患者未确诊。除皮肤外观病变外，白癜风会给患者带来沉重情绪与心理负担，极易诱发焦虑、抑郁、社交隔离。当前临床治疗手段稀缺，皮损面积较大患者可选方案极少；目前仅一款外用药物获批，且仅适用于皮损面积不超过体表面积10%的患者。大量白癜风患者无法得到充分治疗，临床亟需可实现持久、显著色素复色的全身系统治疗药物。关于Teva Teva Pharmaceutical Industries Ltd.（纽交所、特拉维夫证券交易所上市代码：TEVA）依托全球顶尖仿制药业务，正向领先创新生物制药企业转型。120余年来，公司始终深耕健康领域，业务覆盖神经科学、免疫学创新药物研发，同时在全球供应复杂仿制药、生物类似药及自有品牌药房制剂，持续满足当下及未来患者医疗需求。Teva，全心守护大众健康。

100 项与贝前列素钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01551	贝前列素钠	B01AC19	DB05229

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
外周血管疾病	中国	Toray Industries, Inc.	2003-08-15
肺性高血压	日本	Kaken Pharmaceutical Co., Ltd.	1999-09-22
肺动脉高压	日本	Toray Industries, Inc.	1999-09-22
动脉闭塞	日本	Kaken Pharmaceutical Co., Ltd.	1992-01-21
动脉闭塞	日本	Toray Industries, Inc.	1992-01-21

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肾小球疾病	临床3期	中国	Toray Industries, Inc.	2010-03-01
肾小球疾病	临床3期	日本	Toray Industries, Inc.	2010-03-01
肾小球疾病	临床3期	中国香港	Toray Industries, Inc.	2010-03-01
肾小球疾病	临床3期	马来西亚	Toray Industries, Inc.	2010-03-01
肾小球疾病	临床3期	韩国	Toray Industries, Inc.	2010-03-01
肾小球疾病	临床3期	中国台湾	Toray Industries, Inc.	2010-03-01
肾小球疾病	临床3期	泰国	Toray Industries, Inc.	2010-03-01
终末期肾脏病	临床3期	中国	Toray Industries, Inc.	2010-03-01
终末期肾脏病	临床3期	日本	Toray Industries, Inc.	2010-03-01
终末期肾脏病	临床3期	中国香港	Toray Industries, Inc.	2010-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00989963 (CTgov)	临床2期	家族性肺动脉高压 \| 肺动脉高压	36	Beraprost Sodium Modified Release	餘顧鏇膚積醖襯構醖夢(壓築膚築憲醖觸鑰齋襯) = 夢選顧夢壓壓範構壓選夢製鏇觸憲憲築膚膚獵 (廠膚積夢選簾蓋遞衊膚, 3.21) 更多	-	2020-09-30
NCT00792571 (CTgov)	临床2期	肺动脉高压	18	Beraprost Sodium	構鬱廠鑰積鹽廠顧鹽夢 = 蓋齋觸壓製醖廠廠蓋壓醖醖鬱築願糧鏇糧夢觸 (鏇顧膚願鹽餘壓鹹繭廠, 齋製衊築鹹範蓋選繭窪 ~ 淵鬱鬱鹽鹽觸觸襯窪廠) 更多	-	2019-12-26
NCT00990314 (CTgov)	临床2期	肺动脉高压	31	Beraprost Sodium	鑰壓簾廠鏇窪壓簾膚鏇 = 夢遞選膚遞醖夢願觸餘艱蓋窪廠膚鹹選憲齋構 (鑰繭鹽選網鑰獵齋壓願, 蓋廠鏇糧襯遞網積鑰醖 ~ 顧襯簾廠醖願網範鹹範) 更多	-	2019-09-16
NCT02480751 (Pubmed \| BMC Nephrol) 人工标引	临床2期	慢性肾病	112	beraprost sodium 120 μg/d	鑰齋蓋鬱觸衊範艱鏇鹹(憲願繭淵壓築憲衊獵顧) = the slope of regression line of 1/SCr, elevation of SCr and serum cystatin C during the treatment period revealed greater improvement at 120 μg, at both doses, and at 240 μg, respectively 觸艱觸構簾鬱願夢積壓 (鹹憲廠簾簾鹽廠壓艱淵 )	积极	2015-10-16
NCT02480751 (Pubmed \| BMC Nephrol) 人工标引	临床2期	慢性肾病	112	Placebo		积极	2015-10-16
BEAT study (ERS2015)	临床3期	-	-	Beraprost-314d	鹹鏇鏇夢窪憲鑰顧鹹積(糧構鏇鏇鏇餘鬱鏇艱窪) = Beraprost-314d relaxed constricted PAs with a 4-fold greater potency than beraprost 衊簾選範積憲鬱遞襯製 (膚鬱鏇簾膚膚鹹襯鑰願 ) 更多	-	2015-09-01
BEAT study (ERS2015)	临床3期	-	-	Beraprost		-	2015-09-01
P-IIb/III study of BPS (ASN2013)	临床2/3期	终末期肾脏病 \| 肾小球肾炎	-	Beraprost Sodium (GN rats)	壓顧鹹淵築壓選獵獵築(憲襯顧淵鏇築憲餘廠鏇) = 獵蓋壓鏇醖壓壓顧蓋繭獵憲願鹹範憲齋壓願襯 (壓糧齋遞鑰鬱網繭獵憲 )	积极	2013-11-05